Given the success of Research Topic
Advances in Chemotherapy-Resistant Hepatocellular Carcinoma and the rapidly evolving subject area, we are pleased to announce the launch of Volume II.
Primary liver cancer, including hepatocellular carcinoma and cholangiocarcinoma, has a poor prognosis. According to the American Cancer Society statistics, the five-year survival rate of liver cancer is less than 20%. Chemotherapy is the preferred method to kill residual cancer cells after surgery and prolong the survival time of inoperable patients, but most cases are insensitive to chemotherapeutic agents, which leads a poor efficacy and restricts the widespread clinical application of chemotherapy in liver cancers. The reason is that liver cancer cells have primary resistance to chemotherapy drugs or acquired resistance in the process of treatment.
In recent years, the mechanism of chemotherapy resistance to liver cancer has gradually become clear with more and more studies on it, and new combined chemotherapy schemes have also been emerging. These have brought new hope for reversing the chemotherapy resistance of liver cancer. Therefore, this topic will focus on the related content of reversing the chemotherapy of primary liver cancer chemotherapy and face the clinical research and basic research of primary liver cancer chemotherapy.
The Research Topic aims to further clarify the mechanism of chemotherapy resistance to liver cancer, and then find potential therapeutic targets and new combined drug regimens for liver cancer chemotherapy.
We welcome submissions of Original Research, Review articles, and Case Reports with important value in improving the chemotherapeutic efficacy of primary liver cancer will also be considered. Topics of interest include but are not limited to:
• Mechanism of chemoresistance in primary liver cancer.
• Design and application of individualized chemotherapy for primary liver cancer.
• Application of combined chemotherapy regimens, including molecular targeting inhibitors, other chemotherapy drugs, herbal monomers, etc., in primary liver cancer.
• Development of biomaterials-based nanoparticles for chemotherapeutic drug delivery for primary liver cancer treatment.
• Establishment and application of chemoresistance model in primary liver cancer.
